Skip to main content

Table 3 Costs by cost category, mean costs and cost differences discounted, adjusted and unadjusted, given in € (2015)

From: Cost-effectiveness analysis (CEA) of IMRT plus C12 boost vs IMRT only in adenoid cystic carcinoma (ACC) of the head and neck

  mean costs (SD) per patient  
category standard (IMRT only) [€] SD (IMRT only) experimental (IMRT + C12) [€] SD (IMRT + C12) mean cost difference [€] 95% CI, non-parametric bootstrapping (€) p-value
initial treatment 5.68 17.88 11.2  
diagnostic follow-up 2.66 1.47 3 1.11 332 − 219; 955 0.165
treatment of recurrence
 surgery 2.03 6.37 4.82 8.35 2.78 8; 6.039 0.002
 re-RT 2.18 4.92 4.93 11.98 2.75 − 813; 6.376 0.179
 chemotherapy 3.03 3.42 2.46 3.3 − 572 − 2023; 834 0.378
 palliative RT 105 287 103 267 −3 − 131; 105 0.688
total complication costs 7.35 8.51 12.31 16.99 4.95 192; 10,501 0.019
mean total costs (unadjusted)
 undiscounted 15.76 9.17 33.97 17.55 18.15 12,770; 23,745 0.000
 3.5% discount p.a. 14.75 7.95 32.86 14.83 18,076 13,416; 22,922 0.000
 3.0% discount p.a. 14.88 8.1 32.13 15.18 17.25 12,551; 21,946 0.000
mean total costs (adjusted Lin1)
 adjusted (3 monthly intervals) 16.16   38.98   22.82   
 adjusted annually 12.11   36.71   24.6   
 3.5% discount p.a. 11.68   33.71   22.03   
 3.0% discount p.a. 11.74   34.09   22.35